Demis Hassabis, cofounder of DeepMind and 2024 Nobel Laureate, talks to Fortune about his AI drug discovery startup, ...

Isomorphic Labs says it is advancing drug design programs across multiple therapeutic areas and drug modalities. These ...

The new policies include a six-month delay on some research papers and mandate several approval steps before publishing. This process slows down the researchers from sharing their work. Former ...

The London-based business – which launched in 2021 – will use the funds to further its research, expand its team and continue ...

Google DeepMind launches TxGemma, open AI models to speed up drug discovery, enhance predictions, and support multi-step ...

Singapore researchers are using Google DeepMind’s AlphaFold to understand the intricate protein interactions at play in ...

AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict ...

Demis Hassabis, a childhood chess prodigy, said his experience with the game afforded him his first brush with AI. He was ...

Google DeepMind CEO Demis Hassabis's AI journey had an unexpected start: his early mastery of chess. Years before Hassabis ...

Thousands of 3D protein structures locked up in big-pharma vaults will be used to create a new AI tool that won’t be open to ...

The drug discovery company, which has partnerships with Eli Lilly and Novartis, is developing AI models to design drugs and ...